Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

Researchers from the University College Cork have described the neuroprotective effect of TMP-269, a class-IIa-specific histone deacetylase (HDAC) inhibitor in preclinical models of PD. Pan-inhibitors ...

Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These molecules do more than fuel the body—they directly influence gene expression and ...

GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a specialty pharmaceutical company with a current market capitalization of $3.08 million, has reached a milestone in its Phase ...

Melanoma is responsible for about 80% of skin cancer deaths worldwide, particularly in cases with metastasis. Melanoma shows ...

The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.

Detailed price information for Windtree Therapeutics Inc (WINT-Q) from The Globe and Mail including charting and trades.